TITLE

Cholinesterase Inhibitors and Adverse Pulmonary Events in Older People with Chronic Obstructive Pulmonary Disease and Concomitant Dementia A Population-Based, Cohort Study

AUTHOR(S)
Stephenson, Anne; Seitz, Dallas P.; Fischer, Hadas D.; Gruneir, Andrea; Bell, Chaim M.; Gershon, Andrea S.; Longdi Fu; Anderson, Geoff M.; Austin, Peter C.; Rochon, Paula A.; Gill, Sudeep S.
PUB. DATE
March 2012
SOURCE
Drugs & Aging;2012, Vol. 29 Issue 3, p213
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Cholinesterase inhibitors (ChEIs) are a mainstay treatment for individuals with dementia. ChEIs may worsen airflow obstruction because of their pro-cholinergic properties. Objective: The objective of this study was to evaluate the risk of serious pulmonary complications in the elderly with concomitant chronic obstructive pulmonary disease (COPD) and dementia who were receiving ChEIs. Methods: This was a population-based, cohort study conducted between 2003 and 2010 in residents of Ontario, Canada. Subjects were over the age of 66 years and had concomitant dementia and COPD, identified using linked administrative databases. Exposure to ChEIs was determined using a drug benefits database. The primary outcome was an emergency room (ER) visit or hospitalization for COPD. The risk difference at 60 days and the relative risk (RR) for study outcomes were estimated in the propensity score-matched sample. Results: Of 266 840 individuals with COPD, 45 503 had a concomitant diagnosis of dementia. A total of 7166 unexposed subjects were matched to subjects newly exposed to ChEIs. New users of ChEIs were not at significantly higher risk of ER visits or hospitalizations for COPD (RR 0.90; 95% CI 0.76, 1.07) or COPD exacerbations (RR 1.02; 95% CI 0.91, 1.15). Furthermore, ER visits for any respiratory diagnoses were not increased among new users of ChEIs (RR 1.02; 95% CI 0.87, 1.19) when compared with non-users. Subgroup analyses were consistent with the main analysis. Conclusions: In a large cohort of elderly individuals with COPD and dementia, new users of ChEIs had a similar risk for adverse pulmonary outcomes as those who were not receiving ChEIs.
ACCESSION #
74315263

 

Related Articles

  • Effects of guideline-oriented pharmacotherapy in patients with newly diagnosed COPD: a prospective study. Chiang, Chi-Huei; Liu, Shiou-Ling; Chuang, Chiao-Hui; Jheng, Yi-Han // Wiener Klinische Wochenschrift;Jul2013, Vol. 125 Issue 13/14, p353 

    Background: Whether guideline-oriented pharmacotherapy prevents the decline in pulmonary function or reduces systemic inflammation associated with chronic obstructive pulmonary disease (COPD) is uncertain. Objectives: The aim of this study was to assess the outcome of COPD in clinical practice...

  • Cognitive Pharmacotherapy of Alzheimer's Disease and Other Dementias. Herrmann, Nathan // Canadian Journal of Psychiatry;Oct2002, Vol. 47 Issue 8, p715 

    Objective: The objective of this paper is to review the randomized controlled trials (RCTs) on the pharmacotherapy of Alzheimer's disease and other dementias and to provide evidence-based recommendations for treatment of the cognitive impairment associated with these disorders. Method: A Medline...

  • Demência na doença de Parkinson. Caixeta, Leonardo; Vleira, Renata Teles // Revista Brasileira de Psiquiatria;dez2008, Vol. 30 Issue 4, p375 

    Objective: The concomitant presence of psychiatric syndromes, including dementia, with motor disturbance has been increasingly recognized during the last decade, with emphasis on cognitive impairment in idiopatic Parkinson's disease. This review will focus on the epidemiology, clinical aspects,...

  • Kronik AkciÄŸer Hastalığı Olan Hastaların Bronkodilatatör Ä°laçlara Uyumu. Çörtük, Mustafa; Kiraz, Kemal // Journal of Harran University Medical Faculty;2014, Vol. 11 Issue 2, p92 

    Background: Inhaler drugs commonly used because of low side effects for chronic lung disease. There are many different types of inhaler drugs which each is used differently. Patient compliance is also in variable levels for these forms of drugs according to our clinical observation. The aim of...

  • Sexual Dysfunction in Men with COPD: Impact on Quality of Life and Survival. Collins, Eileen; Halabi, Sahar; Langston, Mathew; Schnell, Timothy; Tobin, Martin; Laghi, Franco // Lung;Oct2012, Vol. 190 Issue 5, p545 

    Background: Most patients with chronic obstructive pulmonary disease (COPD) are middle-aged or older, and by definition all have a chronic illness. Aging and chronic illness decrease sexual interest, sexual function, and testosterone levels. To date, researchers have not simultaneously explored...

  • Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma. BRUNETTI, LUIGI; POIANI, GEORGE; DHANALIWALA, FATEMA; POPPITI, KRISTEN; HAENAM KANG; DONG-CHURL SUH // American Journal of Health-System Pharmacy;6/15/2015, Vol. 72 Issue 12, p1026 

    Purpose. Results of a prospective study comparing clinical outcomes and costs of levalbuterol versus albuterol therapy for exacerbations of asthma or chronic obstructive pulmonary disease (COPD) are presented. Methods. In a single-center open-label study, selected adults hospitalized for asthma...

  • A Method for Partitioning the Attributable Fraction of Multiple Time-Dependent Coexisting Risk Factors for an Adverse Health Outcome. Lin, Haiqun; Allore, Heather G.; McAvay, Gail; Tinetti, Mary E.; Gill, Thomas M.; Gross, Cary P.; Murphy, Terrence E. // American Journal of Public Health;Jan2013, Vol. 103 Issue 1, p177 

    Objectives. We decomposed the total effect of coexisting diseases on a timed occurrence of an adverse outcome into additive effects from individual diseases. Methods. In a cohort of older adults enrolled in the Precipitating Events Project in New Haven County, Connecticut, we assessed a...

  • Review of COPD and comorbidities. Dahlan, Zulkarnain // Critical Care & Shock;Aug2012, Vol. 15 Issue 3, p73 

    The article discusses on Chronic Obstructive Pulmonary Disease (COPD) and comorbidities, two or more diseases existing at the same time in the body. The author explains on the presence of comorbidities in people suffering from this disease. The management of this disease is also explained in...

  • Comorbidities Increase Death Rate for COPD Patients.  // AARC Times;Aug2012, Vol. 36 Issue 8, p61 

    The article reports a study by Miguel Divo that comorbidities are common and increase the rate of death among patients with chronic obstructive pulmonary disorder (COPD), including congestive heart failure, coronary artery disease, liver cirrhosis, diabetes with neuropathy, and cancer.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics